Myosin Therapeutics Selected for 2026-2027 NCI Investor Initiatives Showcase
JUPITER, Fla., Sept. 16, 2026 /PRNewswire/ -- Myosin Therapeutics, Inc., a clinical-stage biotechnology company developing a new class of therapies targeting cancer cell mechanics, today announced its selection as a 2026–2027 National Cancer Institute (NCI) Investor Initiatives Showcase...